Drugs / CPO-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04931823 | Mar 2021 → Aug 2024 | neoplasm | Conjupro Biotherapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPO-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04931823 ↗ |
| Route | Intravenous | “CPO-100 administered intravenously” NCT04931823 ↗ |